side effects include:
atrial fibrillation
hypotension
mi
atrial flutter
ventricular extrasystoles
tachycardia
ventricular tachycardia
heart failure
pericarditis
peripheral edema
fever
infection
nausea
lung disorder
pleural effusion
atelectasis
aprotinin
active ingredient
trasylol
clinical studies
patients
receiving aprotinin
adverse effect
patients
receiving placebo therapy
side effects
clinical studies
ones
cardiac surgery
making
definite causal relationship with aprotinin
retrospective review of patient records
documented reexposure
aprotinin
active ingredient
trasylol
incidence in hypersensitivity/anaphylactic reactions
patients
records
hours
days
experiencing
hypersensitivity/anaphylactic reaction
causal relationship with aprotinin
review
chance of a hypersensitivity/anaphylactic side effect
cases
reexposure
months of initial aprotinin administration
reexposure
months from initial administration
hypersensitivity side effects
skin eruptions
itching
dyspnea
nausea
tachycardia
fatal anaphylactic shock with circulatory failure
cardiovascular
side effects for aprotinin
active ingredient
trasylol
relation
placebo therapy
atrial fibrillation
hypotension
myocardial infarct
atrial flutter
ventricular extrasystoles
tachycardia
ventricular tachycardia
heart failure
pericarditis
peripheral edema
hypertension
arrhythmia
supraventricular tachycardia
atrial arrhythmia
thrombosis
shock
cerebrovascular accident
thrombophlebitis
deep thrombophlebitis
).
ventricular fibrillation
heart arrest
bradycardia
congestive heart failure
hemorrhage
bundle branch block
myocardial ischemia
ventricular tachycardia
heart block
pericardial effusion
ventricular arrhythmia
shock
pulmonary hypertension
patients
occlusion of vascular grafts
including
coronary-bypass grafts
addition
being
clinical trials
thrombosis
uncontrolled trials
compassionate use trials
spontaneous postmarketing reporting
reports
term thrombosis
following conditions
thrombosis
occlusion
arterial thrombosis
pulmonary thrombosis
coronary occlusion
embolus
pulmonary embolus
thrombophlebitis
deep thrombophlebitis
cerebrovascular accident
cerebral embolism
myocardial infarction
incidence
patients
aprotinin
patients
placebo
difference in incidence rates
multicenter
multinational study
increase in the risk of graft closure
p =-rrb- in patients
undergoing primary cabg surgery
aprotinin
placebo
study
u.
s.
centers
significant difference in graft closure rates of aprotinin
treated patients
patients
placebo
other side effects for aprotinin
active ingredient
trasylol
relation
placebo therapy
fever
infection
chest pain
sepsis
death
multi-system organ failure
immune system disorder
patients
hemoperitoneum
hematologic side effects for aprotinin
active ingredient
trasylol
relation
placebo therapy
anemia
).
leukocytosis
thrombocytopenia
coagulation disorder
including
disseminated intravascular coagulation
prothrombin
patients
addition
severe diffuse venous thromboembolism
aprotinin administration in patients
factor v leiden
respiratory side effects for aprotinin
active ingredient
trasylol
relation
placebo therapy
lung disorder
pleural effusion
atelectasis
dyspnea
pneumothorax
asthma
hypoxia
lung edema
pulmonary embolus
).
pneumonia
apnea
cough
lung edema
patients
renal side effects for aprotinin
active ingredient
trasylol
relation
placebo therapy
abnormal kidney function
kidney failure
acute kidney failure
kidney
tubular necrosis
).
metabolic side effects for aprotinin
active ingredient
trasylol
relation
placebo therapy
increase in creatine phosphokinase
).
hyperglycemia
hypokalemia
hypervolemia
acidosis
patients
hepatic side effects for aprotinin
active ingredient
trasylol
relation
placebo therapy
abnormal liver function tests
).
jaundice
hepatic failure
patients
nervous system
side effects for aprotinin
active ingredient
trasylol
relation
placebo therapy
confusion
insomnia
asthenia
agitation
dizziness
anxiety
convulsion
patients
nonspecific musculoskeletal side effects
patients
receiving aprotinin
active ingredient
trasylol
receiving placebo therapy
arthralgia
patients
receiving aprotinin
gastrointestinal side effects for aprotinin
active ingredient
trasylol
relation
placebo therapy
nausea
constipation
vomiting
diarrhea
).
dyspepsia
gastrointestinal hemorrhage
patients
genitourinary side effects for aprotinin
active ingredient
trasylol
relation
placebo therapy
urinary retention
urinary tract infection
oliguria
patients
dermatologic side effects for aprotinin
active ingredient
trasylol
relation
placebo therapy
rash
skin discoloration
side effects of trasylol
fda
healthcare professional for medical advice